The goals of the ASCCP Risk-Based Management Consensus Guidelines are to increase accuracy and reduce complexity for providers and patients. Do the new guidelines still use algorithms? The new guidelines rely on individualized assessment of risk taking into account past history and current results.

Risk-based Management Guidelines for the abnormal screening results, including post-colposcopy or post-treatment scenarios. Enduring Guidelines apply this approach to new technologies that emerge and novel clinical scenarios that were not previously addressed.

ASCCP recently released its Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. The new consensus guidelines were developed with input from 19 stakeholder organizations, including ACOG.

The 2019 ASCCP guidelines align management recommendations with current understanding of HPV natural history and cervical carcinogenesis.

ASCCP supports the American Cancer Society (ACS) cervical cancer screening guidelines. Endorsement of a peer organization’s clinical document denotes that ASCCP fully supports the clinical guidance in the document. Clinical documents endorsed by ASCCP are considered official ASCCP clinical guidance.

This Research Letter summarizes all updates to the 2019 guidelines through September 2023, including: endorsement of the 2021 Opportunistic Infections guidelines for HIV+ or immunosuppressed patients; clarification of use of HPV testing alone for ...

The ASCCP guidelines help determine the risk of developing cervical intraepithelial neoplasia grade 3 or worse (CIN3+), including CIN3, adenocarcinoma in situ, and invasive cervical cancer, and...

2024年3月11日 · The American Society of Colposcopy and Cervical Pathology (ASCCP), has published their enduring consensus guidelines and now recognizes the use of p16/Ki-67 dual-stain biomarkers (CINtec® PLUS Cytology) as an important technology to help clinicians triage patients and determine if their human papillomavirus (HPV) infection is transforming into c...

2020年11月20日 · Describe the risk-based paradigm for managing abnormal cervical cancer screening test results. What’s In the 2019 ASCCP Guidelines? developed and finalized? What were the “fundamental concepts” used in 2019 Guideline development? Egemen D, et al.. (2020). Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines.

Updated US consensus guidelines for management of cervical screening abnormalities are needed to accommodate the 3 available cervical screening strategies: primary human papillomavirus (HPV) screening, cotesting with HPV testing …